An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 24 Mar 2025
At a glance
- Drugs BMS 986158 (Primary) ; Dexamethasone (Primary) ; Mezigdomide (Primary) ; Tazemetostat (Primary) ; Trametinib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb; Celgene Corporation
Most Recent Events
- 19 Mar 2025 Protocol was amended to remove an arm i.e. Part 2 Arm F: Dose Expansion.
- 19 Mar 2025 Planned number of patients changed from 220 to 160.
- 19 Nov 2024 According to a Bristol Myers Squibb media release, results from this trial will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held from December 7 to 10 in San Diego, California.